Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate.
about
Comprehensive analysis of PPARalpha-dependent regulation of hepatic lipid metabolism by expression profilingSorting out the roles of PPAR alpha in energy metabolism and vascular homeostasisMajor urinary protein-1 increases energy expenditure and improves glucose intolerance through enhancing mitochondrial function in skeletal muscle of diabetic miceFenofibrate and PBA prevent fatty acid-induced loss of adiponectin receptor and pAMPK in human hepatoma cells and in hepatitis C virus-induced steatosisFenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a reviewThe impact of PPARα activation on whole genome gene expression in human precision cut liver slicesPPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a.Time-resolved and tissue-specific systems analysis of the pathogenesis of insulin resistance.Alterations of anti-inflammatory lipids in plasma from women with chronic widespread pain - a case control studyMolecular pathways in non-alcoholic fatty liver disease.A systems biology strategy for predicting similarities and differences of drug effects: evidence for drug-specific modulation of inflammation in atherosclerosis.PPARs, Obesity, and InflammationUnraveling the complex relationship triad between lipids, obesity, and inflammationThe Role of PPARα Activation in Liver and Muscle.The G0/G1 switch gene 2 is a novel PPAR target gene.A dietary mixture containing fish oil, resveratrol, lycopene, catechins, and vitamins E and C reduces atherosclerosis in transgenic mice.Agonistic antibody to angiotensin II type 1 receptor accelerates atherosclerosis in ApoE-/- mice.PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammationVesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent.Suppression of hepcidin during anemia requires erythropoietic activity.Evaluation of gene expression profiling in a mouse model of L-gulonolactone oxidase gene deficiency.The connection between C-reactive protein and atherosclerosisPeroxisome proliferator-activated receptorα agonists differentially regulate inhibitor of DNA binding expression in rodents and human cells.Fenofibrate inhibited the differentiation of T helper 17 cells in vitro.Peroxisome Proliferator Activated Receptor-α Agonist Slows the Progression of Hypertension, Attenuates Plasma Interleukin-6 Levels and Renal Inflammatory Markers in Angiotensin II Infused MicePPARalpha in atherosclerosis and inflammation.Therapeutical effects of PPAR agonists assessed by biomarker modulation.Inflammation, thrombosis and acute coronary syndromes.PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia.Peroxisome Proliferator-Activated Receptor-α Agonism With Fenofibrate Does Not Suppress Inflammatory Responses to Evoked Endotoxemia.DAP12 (KARAP) amplifies inflammation and increases mortality from endotoxemia and septic peritonitis.Interleukin-6 is essential for primary resistance to Francisella tularensis live vaccine strain infection.Nuclear control of the inflammatory response in mammals by peroxisome proliferator-activated receptorsPPARs and molecular mechanisms of transrepressionMeasuring biomarkers to assess the therapeutic effects of PPAR agonists?Peroxisome proliferator-activated receptors--from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease.Gene modulation associated with inhibition of liver regeneration in hepatitis B virus X transgenic miceNeutrophils as one of the major haptoglobin sources in mastitis affected milk.Statins and nitric oxide reduce C-reactive protein production while inflammatory conditions persistGlycogen synthase 2 is a novel target gene of peroxisome proliferator-activated receptors.
P2860
Q21342976-15014203-1FA1-444E-9145-EFB0B686F893Q24541529-9C0ECCA9-DC03-43AA-B73F-7B0094BB0E57Q24642546-ABE97EBA-8D6E-4C5C-84D6-89F501ACE835Q27489896-F7CC1E2D-4F59-4719-9591-68C807D96012Q28220294-FA0CCAB9-4AD6-4BDD-B0C0-DDBB117F1CC6Q28606579-5C9DDB69-7B3D-467E-8A39-5781A216C3E2Q30476274-30E8EDD1-7C63-4FDB-96BC-AD11E4FD0229Q33526310-07308926-7A3B-4C4B-8183-A51CC1FC525CQ33791893-A29F294C-3375-48C9-9B09-820DD2D22A85Q33890230-61DAC8D7-62E2-4C99-90E3-F46C1EC2730CQ33991958-8081225A-7CC8-46BC-A8F2-E58602D8A09EQ34003196-54714C77-2097-4CFD-B71F-CAA9A5755760Q34042152-26A25912-70A2-4589-9DFD-E264113745DBQ34106233-7B9699F4-85CF-48E6-BDBE-48E168962476Q34441198-040B4890-F101-4E7D-A820-3EBA24C95C68Q34802107-5D1B0973-96DF-43BC-9C29-3F0DB0A5A67EQ34978758-3AD1AFF4-5E23-49C9-B3B9-EC2949D93F75Q35053566-E8AF9B41-1EAF-464D-9482-4756CEAA0B2BQ35275179-F8C9CC54-3696-4EFF-B981-8DDF758AD22AQ35848905-7A94BF4A-2822-49FB-BB17-05749EF8BC9BQ35944435-CDB719B1-15DA-4D02-97D9-80C40F2CECE0Q35999439-95956330-C51D-4354-9FFE-E7CDCCB4463EQ36026632-015592F0-CB25-4932-86FA-1BBBB253C62FQ36072203-2D27C0A4-3546-4F77-A633-33D271A0F5F7Q36119361-B034335F-7EE4-4CFD-91D3-DE5E026CD351Q36154953-8F953989-63B8-4FCA-83B1-7805937CFACDQ36317991-DDA1B429-0AD3-4FF5-A021-AB0836EDFBE9Q36333915-BD970BCA-7832-483D-9374-67393EA3DA2FQ36360452-E46CFF10-AF95-47F3-8492-C0D2917DBCB3Q36366326-3FAFAC92-BFE5-4EE2-A320-A0EA9C353AF1Q36403308-8D8176AA-3C56-4E19-AB80-84FA70E2D905Q36558802-48563CA0-79EB-460D-99AD-3F7AB26F51E8Q36733873-D00334A1-12F3-4F28-BCAC-522036596E17Q36791361-8C7F6C99-B925-4427-826B-238FF13E90C9Q37012012-889D6B02-6B0B-4077-8204-8948C17A30C8Q37016305-EE1732F2-E1F9-4276-9C1C-3F84C8F6FF75Q37189594-E6F79F86-84AE-400F-8479-9C7018E50231Q37224077-7EFFD3BF-A1D6-4E34-945A-12A397A1ABDCQ37281358-C621FE07-22E5-4E7D-BE2C-D16C3E10DC93Q37407233-BEACFA93-9736-46EB-B6D9-19E6A5AD460C
P2860
Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Global suppression of IL-6-ind ...... r-alpha activator fenofibrate.
@en
Global suppression of IL-6-ind ...... r-alpha activator fenofibrate.
@nl
type
label
Global suppression of IL-6-ind ...... r-alpha activator fenofibrate.
@en
Global suppression of IL-6-ind ...... r-alpha activator fenofibrate.
@nl
prefLabel
Global suppression of IL-6-ind ...... r-alpha activator fenofibrate.
@en
Global suppression of IL-6-ind ...... r-alpha activator fenofibrate.
@nl
P2093
P2860
P356
P1476
Global suppression of IL-6-ind ...... r-alpha activator fenofibrate.
@en
P2093
Antoine Pilon
Frédéric Percevault
Philippe Gervois
Robert Kleemann
Teake Kooistra
P2860
P304
16154-16160
P356
10.1074/JBC.M400346200
P407
P577
2004-02-05T00:00:00Z